Opthea was making preparations for the potential launch of a new eye disease drug onto the market. | A month ago, Opthea was ...

Australian-US biotech Opthea Ltd has reported disappointing phase 3 results with its lead drug for vision-robbing disease wet ...

Leerink downgraded Opthea (OPT) to Market Perform from Outperform with a price target of $1, down from $12. The firm cites the company ...

Opthea (ASX:OPT) has announced that its lead drug candidate sozinibercept has failed to meet primary endpoints in a phase 3 ...

Three drugs — Eylea, Lucentis and Avastin—were compared. All three performed similarly for people with mild DME, while Eylea did better for those who had moderate or worse vision loss. There were 660 ...

Macular degeneration, particularly age-related macular degeneration (AMD), is a leading cause of vision loss worldwide. This ...

Regeneron Pharmaceuticals (NASDAQ:REGN) dropped 1.6% after the company's loss against Amgen (NASDAQ:AMGN) in a patent case over Regeneron's blockbuster Eylea drug was affirmed by an appeals court.

Regeneron Pharmaceuticals announced positive three-year results from an extension study of EYLEA HD (aflibercept) Injection 8 mg for treating wet age-related macular degeneration (wAMD).

The treatment is a biosimilar that could compete with Regeneron Pharmaceuticals’ Eylea. Teva and Alvotech have been working together in a strategic partnership since 2020. Teva Pharmaceutical ...